Post Profile






Bladder Cancer Research Rife with New Approaches

The FDA approval of Tecentriq ushered in the first new treatment for advanced bladder cancer in 30 years.
read more

share

Related Posts


F.D.A. Approves an Immunotherapy Drug for Bladder Cancer

Health : NYTimes: Health

The drug, Tecentriq from Roche, works by using the body’s immune system against tumors, and is the first drug of its type approved for bladder cancer.

The FDA just approved a revolutionary kind of drug to treat bladder cancer for the first time

Business & Finance : Business Insider: Clusterstock

The FDA on Wednesday approved a new kind of drug to treat the most common form of bladder cancer. The drug, which goes by the name Tecentriq and was developed by Genentech, is a cancer immunotherapy. Unlike chemotherapy, which invol...

Merck's Keytruda succeeds in key bladder cancer trial

Health : Reuters: Health

(Reuters) - Merck & Co Inc said its immunotherapy, Keytruda, helped previously treated patients with advanced bladder cancer live longer in a late-stage study, prompting an independent monitoring panel to recommend stopping the tria...

Yale Cancer Center Expert Available to Discuss the FDA Approval of Tecentriq in the Treatment of Bladder Cancer.

Medical News Today: FDA approve immunotherapy drug for bladder cancer

Health : Medical News Today

The FDA have given accelerated approval to Tecentriq (atezolizumab), a PD-1/PD-L1 inhibitor, to treat urothelial carcinoma, the most common type of bladder cancer.

Comments


Copyright © 2016 Regator, LLC